ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
56 announcements
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
Dr. Lal PathLabs discloses share transactions by designated persons and an employee welfare trust under PIT regulations.
Designated persons at Dr. Lal PathLabs Ltd disclosed three equity trades totaling Rs. 0.50 Crore, as mandated under Insider Trading regulations.
Designated persons of Dr. Lal PathLabs Ltd sold equity shares worth a combined ₹0.49 Crore via market sales.
Designated persons and the employee welfare trust of Dr. Lal PathLabs Ltd disclosed share transactions under PIT Regulations. These trades involve ESOP-related activities and market sales.
Dr. Lal Path Labs Ltd.'s subsidiary completed a 30% stake subscription in Neuome Technologies Private Limited for ₹3.50 Crore, making Neuome an associate company.
Dr. Lal PathLabs' subsidiary, Dr. Lal Ventures, has completed the acquisition of a 30% stake in Neuome Technologies Private Limited.
Designated Person Abhishek Maini acquired 500 equity shares via ESOP and subsequently sold 500 shares. This is a routine regulatory disclosure of personal trading activity.
Dr. Lal PathLabs reported insider trading disclosures for share sales by a designated person and the Employee Welfare Trust. These trades involve 33,350 shares total.
Dr. Lal Path Labs Ltd.'s subsidiary will acquire a 70% stake in Dr Lal PathLabs Indomed LLC to expand its diagnostics services in Uzbekistan.
Dr. Lal PathLabs' subsidiary, Dr Lal PathLabs FZCO, has incorporated a new step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, acquiring a 70% stake.
Dr. Lal PathLabs has allotted 2,11,050 equity shares under its Employee Stock Option Plan 2022. This issuance increases the company's total paid-up equity share capital.
Mr. Gurinder Singh Kalra has completed his tenure as an Independent Director of Dr. Lal PathLabs Limited, effective from July 26, 2026.
Dr. Lal PathLabs held its 32nd Annual General Meeting on July 25, 2026, discussing financial statements, dividend declarations, and various director re-appointments.
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹629.6 Cr (+4.7% YoY) and net profit of ₹165.9 Cr (+28.3% YoY) for Q1 FY27.
Dr. Lal Path Labs has granted 119,300 stock options to eligible employees under its 2025 Restricted Stock Unit Plan.
Dr. Lal Path Labs' subsidiary will acquire an 80% stake in Sunshine Healthcare Limited, Ghana. The transaction is valued at ₹38.0 Crore.
Dr. Lal Path Labs' subsidiary, Dr. Lal Ventures, is acquiring a 30% stake in Neuome Technologies for ₹3.5 Crore. This provides access to innovative bio-banking solutions.
Dr. Lal Path Labs declared an interim dividend of ₹5 per equity share. The record date for payment is July 30, 2026.
Dr. Lal PathLabs reported strong Q1 FY27 results with 19.1% revenue growth and 27.2% PAT growth. Strategy remains focused on scientific leadership, patient experience, and operational excellence.
Dr Lal PathLabs reported Q1 FY27 revenue of ₹798 Crore, growing 19.1% YoY. PAT for the quarter increased to ₹170 Crore.
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹797.7 Cr (+19.1% YoY) and net profit of ₹170.5 Cr (+27.2% YoY) for Q1 FY27.
Dr. Lal PathLabs Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details the distribution of equity shares across various investor categories.
Dr. Lal Path Labs received a favorable Income Tax appellate order for FY 2021-22. The 32.66 Crore ESOP expense deduction was successfully allowed.
Dr. Lal PathLabs received a favorable appellate order from the Income Tax Department. The order allows a tax deduction of Rs.32.66 Crore regarding ESOP expenses.